Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/40/74/2e/40742e6c-6a61-2d95-b634-8dda4a9dba7b/mza_13147460199252821216.jpg/600x600bb.jpg

LifeSci Partners Podcast

LifeSci Partners.com

74 episodes

1 week ago

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

Life Sciences

Science

RSS

All content for LifeSci Partners Podcast is the property of LifeSci Partners.com and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/12716813/12716813-1620938344168-d59435a1debe2.jpg

Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

LifeSci Partners Podcast

26 minutes 46 seconds

3 years ago

Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

Most oncology drugs turn things off—Alligator Bioscience prefers to turn things on, specifically, the immune system, by way of stimulation with CD40 and 4-1BB agonists. In this podcast, Alligator CEO, Søren Bregenholt, discusses the latest clinical data for lead anti-CD40 asset, mitazalimab, as well as two distinct 4-1BB agonists in development. Additionally, he answers the critical question: How did you tame the toxicity of these signaling molecules when so many others have failed?